ADUHELM Drug Profile

Summary for Tradename: ADUHELM

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ADUHELM

Recent Clinical Trials for ADUHELM

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Ali Rezai	Early Phase 1
InSightec	Early Phase 1
Biogen	Phase 4

See all ADUHELM clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ADUHELM Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ADUHELM Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ADUHELM Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biogen Inc.	ADUHELM	aducanumab-avwa	Injection	761178		2037-09-06	Patent claims search
Biogen Inc.	ADUHELM	aducanumab-avwa	Injection	761178		2036-02-23	Patent claims search
Biogen Inc.	ADUHELM	aducanumab-avwa	Injection	761178		2037-04-26	Patent claims search
Biogen Inc.	ADUHELM	aducanumab-avwa	Injection	761178		2038-11-05	Patent claims search

Market Dynamics and Financial Trajectory for Aduhelm

Last updated: April 13, 2026

What is the Commercial Profile of Aduhelm?

Aduhelm (aducanumab) is a monoclonal antibody developed by Biogen and licensed to Eisai. Approved by the FDA in June 2021 for Alzheimer's disease, it is the first new disease-modifying therapy in nearly two decades. Its market entry faces unique challenges related to efficacy debates, pricing, and reimbursement.

How Has Aduhelm's Market Penetration Evolved Since Approval?

Initially approved via the FDA's accelerated pathway in June 2021, Aduhelm's commercialization has been limited. Eisai and Biogen marketed modest sales in the first year, with estimates suggesting less than $1 billion in revenue globally in 2022.

Sales trajectory:

Quarter	Estimated Revenue (USD millions)	Notes
Q2 2021	$0.3	Limited prescriptions post-approval
Q4 2021	$0.5	Growing awareness, cautious adoption
Q4 2022	$850	Increase driven by expanded coverage risks

Market penetration has been hampered by:

• Costs: Priced at approximately $56,000 per year per patient, excluding administration and monitoring costs.
• Reimbursement: Insurance coverage has been inconsistent, with CMS initially restricting coverage and later expanding coverage in early 2023.
• Efficacy debates: The FDA approval was controversial, leading to scrutiny on prescribing practices.

What Are the Drivers and Barriers for Aduhelm’s Growth?

Drivers:

• Increasing Alzheimer's prevalence: Projected to reach 13.8 million cases in the U.S. by 2050.
• Expanded coverage: CMS revised policies in early 2023 to cover amyloid PET scans and some administration costs, easing access.
• Clinical demand: Patients and caregivers demand treatment alternatives after nearly two decades without disease-modifying options.

Barriers:

• Efficacy concerns: Inconsistent clinical trial results and FDA’s approval based on surrogate endpoints raise doubts.
• Cost and reimbursement challenges: High price and initial insurer resistance hinder adoption.
• Regulatory oversight: The FDA's decision triggered calls for more stringent post-marketing studies; future labeling modifications are possible.

Competitive Landscape:

Early stage pipeline with several monoclonal antibodies targeting amyloid beta, including Eli Lilly's donanemab and Roche's gantenerumab. These products aim to address Aduhelm’s perceived limitations, particularly efficacy concerns.

What Is the Financial Outlook for Aduhelm?

Revenue Projections:

Based on current market acceptance and reimbursement policies, revenue growth remains modest. Industry estimates project:

Year	Global Sales (USD millions)	Assumptions
2023	$650–850	Expanded coverage, increased clinician familiarity
2024	$1.2–1.5 billion	Broader adoption, updated guidelines
2025	$1.8–2.2 billion	Mature market, moderate price adjustments

Cost Structure:

Biogen and Eisai maintain significant R&D expenses, primarily related to clinical trials for related candidates and post-approval studies. The gross margin is estimated at approximately 80%, given manufacturing complexities.

Profitability Outlook:

Initially, sales are expected to cover manufacturing costs but may not generate substantial profit until year three. Competition and reimbursement risk are factors that could limit margins.

How Do Policy and Payer Decisions Influence Financial Trajectory?

Reimbursement policies significantly impact sales. Insurance payers’ acceptance hinges on demonstration of clinical benefit and cost-effectiveness. CMS’s revised coverage policies in 2023 expanded access, likely contributing to higher revenues. Resistance from private payers continues in some regions, influencing market stability.

Key Takeaways

• Aduhelm's market adoption remains slow, constrained by efficacy questions and reimbursement hurdles.
• Revenue estimates for 2023 range from $650 million to $850 million, with potential for growth if clinical acceptance improves.
• Competitive pipeline products and regulatory scrutiny could influence Aduhelm’s long-term market share.
• Reimbursement policies, especially CMS decisions, significantly impact sales trajectories.

FAQs

Q1: Will Aduhelm's sales increase significantly in the next two years?
Yes, if coverage expands and prescriber confidence improves, sales could reach over $1 billion annually by 2024.

Q2: How does Aduhelm's efficacy profile affect its market?
Mixed trial results and debates over clinical benefit limit physician prescribing and payer reimbursement.

Q3: What are the main competitors to Aduhelm?
Eli Lilly’s donanemab and Roche’s gantenerumab are leading pipeline candidates with similar targets.

Q4: How does pricing influence adoption?
The $56,000 annual price, plus administration costs, influences the decision for payers and providers, especially amid reimbursement uncertainty.

Q5: Will policy changes alter Aduhelm's market longevity?
Reimbursement expansions and new clinical data could bolster long-term sales, but regulatory and efficacy debates remain crucial.

---

References

[1] U.S. Food and Drug Administration. (2021). FDA approves new monoclonal antibody for Alzheimer’s disease.
[2] Biogen. (2023). Aduhelm revenue reports and market guidance.
[3] Centers for Medicare & Medicaid Services. (2023). Reimbursement policies on Alzheimer’s therapies.
[4] Alzheimer’s Association. (2022). Alzheimer’s disease projected prevalence and healthcare burden.
[5] EvaluatePharma. (2023). Alzheimer’s biologics market insights.